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ABSTRACT
While heart transplantation remains the gold standard therapy for end-stage heart
failure, complications remain common post-transplant. Infection is a common cause of
morbidity and mortality within the first-year post-transplant. ImmuKnow (ViraCor-IBT
Laboratories Inc.) is a cell mediated immunity (CMI) assay utilized in transplant populations to
monitor the degree of immunosuppression. We aimed to determine whether utilization resulted
in lower rates of infection and immunosuppression-related side effects. This was a prospective
interventional trial of transplant patients from June 2018-June 2019. CMI was assessed at
standard time points and adjustments in tacrolimus were made per set protocol. Outcomes
were compared to historical controls. Thirty-one patients were enrolled in the intervention and
control groups. There were no differences in average CMI levels between patients with infection
versus those without infection. There were no significant differences in the number of patients
with infections. Nine patients had bacterial infections within the 1st-year in the interventional
group compared to 12 patients in the control group (p=0.6). Nine patients had a viral infection in
the interventional group versus eight patients in the control group (p=0.7). There were no
differences in rejection episodes between groups. There was no difference between groups in
renal function or blood sugar control over one-year follow up. Use of CMI assay post-heart
transplant did not result in lower incidence of infection nor in differences in renal function or
blood sugar control. Further studies are needed to better evaluate the utility of routine use of
this assay to guide immunosuppression following heart transplant.
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CHAPTER 1: INTRODUCTION
While heart transplantation remains the gold standard therapy for the treatment of
end-stage heart failure, there are more patients listed for transplantation than organs available.1
This means that monitoring and management strategies that aim to reduce graft loss and
mortality following transplantation are vitally important to help improve optimal allocation of
organs and longevity of transplants. Heart transplant recipients require lifelong
immunosuppression to help reduce the risk of graft loss from rejection. Immunosuppression
must be finely balanced to not only avoid rejection, but also minimize the risk of infectious
episodes from over-immunosuppression as well as reduce the development of medicationinduced side-effects and complications.2
Classically, physicians and providers utilize trough levels of immunosuppressants,
laboratory tests assessing white blood cell (WBC) and lymphocyte counts, time since
transplantation, renal function, and rejection and infection history to guide specific
immunosuppressant use and dosing.2,3 However, these strategies do not reliably assess the
patient’s true cellular immune function, with several studies showing immunosuppression doses
and common laboratory variables do not strongly correlate with in-vivo cell-mediated
immunity.4-6 To provide better monitoring of immunosuppression, the Food and Drug
Administration (FDA) approved the use of ImmuKnow (ViraCor-IBT Laboratories Inc., Lee’s
Summit, MO.) in 2002 in solid-organ transplant recipients for better assessment of a recipient’s
cell mediated immunity (CMI). While both retrospective and prospective studies have
investigated the utility of assessing CMI to identity risk of rejection and infection across all types
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of solid organ transplant recipients4-11, there is limited data on any prospective protocol utilizing
this assay in heart transplant recipients.
We aimed to determine whether utilization of a cell-mediated immune assay in a
prospective, protocolized fashion in heart transplant recipients would improve infection and
rejection rates as well as reduce immunosuppression-related side effects in real-world clinical
practice.
CHAPTER 2: METHODS
Study Design
This was a prospective interventional trial comparing outcomes of adult heart transplant
recipients whose immunosuppressive regimen was monitored and adjusted utilizing a cellmediated immune assay to historical controls utilizing previous standard of care. Outcomes
were assessed up to 12 months after transplantation in both the intervention and control
groups. Heart transplant recipients in the intervention group were enrolled from June 2018
through June 2019. Patients receiving a heart transplant from January 2015 through December
2015 were utilized as the historical controls. This study was approved by the institutional review
board at our institution.
Patient Population
Consecutive solitary heart transplant recipients were prospectively monitored for
degree of immunosuppression utilizing the cell-immune assay after a change in our program’s
immunosuppression monitoring policy and algorithm. Multi-organ transplant recipients were
excluded from this policy. Historical controls included all solitary heart transplant recipients
transplanted during the calendar year of 2015 as this as the last year a cell-mediated immunity
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assay was not utilized routinely in a non-protocolized fashion for immunosuppression
monitoring.
Cell Mediated Immunity Testing
We utilized the commercially available ImmuKnow (ViraCor-IBT Laboratories Inc., Lee’s
Summit, MO.) assay which has been approved by the U.S. FDA to measure and monitor
underlying immune response in solid-organ transplant recipients receiving immunosuppressive
therapy. This assay measures cell-mediated immunity via quantification of ATP concentration
released from CD4+ T-lymphocytes. This ATP release is triggered via mitogenic stimulation and
cells are then lysed to release intracellular ATP. Based on previous studies in solid organ
transplant populations, levels of ATP activity of 225 ng/mL or lower indicate a low cellular
immune response, levels of 525 ng/mL or higher indicate a strong cellular immune response,
and levels of 226 ng/mL to 524 ng/mL suggest a moderate cellular immune response.
Cell-mediated immunity was assessed as part of the pre-transplant evaluation process
and repeated every six months as part of waitlist management. Following heart transplantation,
an immune function assay was assessed on post-operative day 1 and with endomyocardial
biopsy collection and/or outpatient visits at weeks 1, 2, 3, 4, 6, and 8, and months 3, 6, 9, and
12.
Immunosuppression and Intervention
Immunosuppression was administered via induction therapy and a triple-drug regimen
according to our institutions standard practice. Induction therapy consisted of basiliximab 20mg
1 hour prior to incision and on post-operative day 4 and 1 g methylprednisolone 1 hour prior to
incision. Post-operative steroid tapering was as follows: methylprednisolone 125mg every 8
hours for six doses followed by prednisone 60mg daily for 2 days, 50mg daily for 2 days, 40mg
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daily for 2 days, 30mg daily for 2 days, and then a maintenance dose of 20mg daily. Prednisone
is gradually decreased and stopped on a patient-by-patient basis over subsequent 6 months.
Methylprednisolone doses were converted into an equivalent prednisone dose for direct
comparison over time between the two groups. Mycophenolate mofetil is initiated on postoperative day 1 at 2000mg per day in recipients 50 years of age or older and 3000mg per day in
recipients younger than 50 years of age.
Tacrolimus was initiated by post-operative day 5 once stable renal function and good
urine output achieved. In historical controls, doses were adjusted in 0.5 to 1mg increments to
achieve a target trough level of 10-12ng/mL early post-operatively and gradually adjusted over
time depending on patient’s glomerular filtration rate and time since transplant as well as
rejection and infection history, generally targeting a trough level of 6-12ng/mL depending on a
combination of these factors. In the intervention group, tacrolimus was also initiated by postoperative day 5 again when renal function was stable, but cell-mediated immunity was utilized
to adjust tacrolimus dose based off the algorithm shown in Table 1. Immune response levels
between 130 and 450ng/mL of ATP were utilized as the target range as these levels have been
shown in several previous trials as thresholds for increased risks of infection or rejection and
have also been used as target goals in a prospective interventional trial in liver transplant
recipients.12
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Time since transplant and
ImmuKnow ranges
0-3 Months
ImmuKnow <130
ImmuKnow 130-450
ImmuKnow > 450
3-12 Months
ImmuKnow <130
ImmuKnow 130-450
ImmuKnow > 450
> 12 Months
ImmuKnow <130
ImmuKnow 130-450
ImmuKnow > 450

Goal FK level in patients with GFR
> 40

Goal FK level in patients with GFR
< 40

8-10 ng/ml
10-12 ng/ml
10-12 ng/ml

6-8 ng/ml
8-10 ng/ml
10-12 ng/ml

6-8 ng/ml
8-10 ng/ml
10-12 ng/ml

4-6 ng/ml
6-8 ng/ml
8-10 ng/ml

4-6 ng/ml
6-8 ng/ml
8-10 ng/ml

4-6 ng/ml
6-8 ng/ml
8-10 ng/ml

Table 1. Tacrolimus adjustment protocol utilizing cellular immune assay in conjunction with
renal function and time post-transplant.
Rejection and Infection
Monitoring for rejection was performed utilizing right ventricular endomyocardial
biopsies as per our program’s standard monitoring schedule at weeks 1-4, 6, 8, and 12 and at 12
months. Gene-expression testing via AlloMap profile (CareDx, Inc., Brisbane, CA) was utilized for
rejection surveillance starting at 4 months with abnormal scores followed up via
endomyocardial biopsy. Rejection was defined as acute cellular rejection (ACR)13 and antibody
mediated rejection (AMR)13,14 utilizing International Society for Heart and Lung Transplantation
(ISHLT) definitions.
We monitored for infection utilizing clinical assessment via history and physical exam
along with laboratory, microbiologic, and imaging studies as clinically indicated. Infection was
defined as signs/symptoms of infection with concurrent microbiologic and/or imaging findings
consistent with infection that required initiation or escalation of antimicrobial therapy for
treatment.
Infection prophylaxis was utilized following heart transplantation and at our center
includes use of trimethoprim/sulfamethoxazole 60mg/800mg thrice weekly for the first 12
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months following transplantation as Pneumocystis carinii and Toxoplasmosis gondii prophylaxis.
Valganciclovir or valacyclovir are utilized depending on donor and recipient cytomegalovirus
(CMV) status for the first 3 months following transplant for CMV prophylaxis.
Outcomes
The primary outcome of our study was the rate of infection and rejection episodes in
the intervention and control groups. Secondary outcomes included one-year survival,
development or progression of post-transplant renal dysfunction (as assessed by need for
dialysis, creatinine level, and glomerular filtration rate (GFR) as measured by the formula: 175 x
(Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African American), development or worsening
of diabetes (worsening hemoglobin A1c), dose of tacrolimus, and addition of proliferation signal
inhibitor.
Statistical Analysis
Baseline continuous variables are presented as mean ± standard deviation and
categorical variables are presented as number and percentage. Baseline characteristics were
compared between the two groups (CMI versus non-CMI) using the independent groups t-test
and nonparametric Mann-Whitney U test for continuous variables and Chi-square test for
categorical variables. Time-to-event analyses were performed utilizing the Kaplan-Meier method
and compared between the two groups using the Logrank test. Linear mixed modeling with
repeated measures over time was used to compare renal function (creatinine and glomerular
filtration rate [GFR]), markers of diabetes control (blood sugar and hemoglobin A1c), FK trough
level, and doses of immunosuppressive agents between the two groups over the course of study
follow up. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary,
NC).
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CHAPTER 3: RESULTS
Patient Characteristics
A total of 33 patients underwent heart transplantation between June 2018 and June 2019. Two
patients underwent dual organ transplantation (heart-kidney) and were thus excluded from this
protocol leaving a total of 31 patients in the intervention group. A total of 33 patients
underwent heart transplantation during calendar year 2015. Two patients underwent dual
organ transplantation (heart-kidney) and were thus excluded from the analysis leaving a total of
31 patients in the control group. Patients in the intervention group had an average age of 54.3
(±13.2) year, 9 (29%) were female sex, 14 (45.2%) had heart failure related to an ischemic
cardiomyopathy, and 14 (45.2%) had been supported by a left ventricular assist device (LVAD) at
the time of transplantation. Compared to the control group, patients in the intervention group
had lower rates of previous smoking (p=0.007), lower rates of kidney dysfunction as evidenced
by lower creatinine (p=0.007) and higher GFR (p=0.01), and lower total bilirubin (p=0.02) at the
time of transplantation. Full baseline characteristics are shown in Table 2.
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Characteristic

Intervention Group
(N=31)
54.3 (13.2)
9 (29)
27 (87.1)
28.8 (4.8)
14 (45.2)
14 (45.2)

Age, yr (SD)
Female Sex, N (%)
White/Caucasian, N (%)
BMI, kg/m2 (SD)
Ischemic Cardiomyopathy, N (%)
Support by LVAD, N (%)
Smoking History, N (%)
Current
0 (0)
Former
16 (51.6)
Never
15 (48.4)
Diabetes Mellitus, N (%)
7 (22.6)
Hypertension, N (%)
17 (54.8)
Hyperlipidemia, N (%)
23 (74.2)
Chronic Kidney Disease, N (%)
8 (25.8)
Laboratory Values
Hemoglobin, g/dL (SD)
11.5 (2.6)
Platelet Count, cells/uL (SD)
215,935.5 (80,007.9)
Sodium, mmol/L (SD)
137.6 (3.5)
BUN, mg/dL (SD)
20.8 (8.3)
Creatinine, mg/dL (SD)
1.1 (0.3)
Glomerular Filtration Rate,
80.2 (30)
mL/min/1.73m2 (SD)
Total Bilirubin, mg/dL (SD)
0.7 (0.4)
Albumin, g/dL (SD)
3.9 (0.6)
Ejection Fraction, % (SD)
30 (15.3)
Right Atrial Pressure, mmHg (SD)
10.9 (6.4)
Wedge Pressure, mmHg (SD)
14.6 (8.9)
Cardiac Index, L/min/m2 (SD)
2.4 (0.5)
Peak VO2, mL/kg (SD)
13.8 (3.4)
VE/VCO2, slope (SD)
35.8 (5.7)
Table 2. Baseline characteristics of study participants.

Control Group
(N=31)
54.7 (14.8)
7 (22.6)
29 (93.5)
28.7 (4.9)
15 (48.4)
21 (67.7)

p-value
0.9
0.6
0.4
0.9
0.8
0.07
0.007

0 (0)
26 (83.9)
5 (16.1)
7 (22.6)
15 (48.4)
22 (71)
10 (32.3)

1
0.6
0.8
0.6

11.3 (2.4)
230,354.8 (61,599.5)
137 (3.1)
21.5 (10.4)
1.4 (0.5)
62.7 (21.5)

0.7
0.4
0.4
0.8
0.007
0.01

1 (0.5)
3.8 (0.8)
26.3 (15.4)
9.2 (5.5)
12.8 (6.6)
2.6 (0.7)
14.8 (5.1)
34.8 (7.1)

0.02
0.8
0.4
0.3
0.4
0.1
0.5
0.6
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CMI Levels
Average CMI levels and standard deviations obtained in the treatment group at standard time
points are displayed in Table 3 as well as graphically to visualize trend in Figure 1.
Time PostTransplant
Day 1
1 Week
2 Weeks
3 Weeks
4 Weeks
6 Weeks
8 Weeks
3 Months
6 Months
9 Months
1 Year

CMI Level
ng/mL (SD)
283.8 (241.2)
366.1 (210.6)
326.6 (188.2)
320 (260.5)
442.6 (280)
375.3 (211.3)
390.6 (204.8)
348.1 (190.8)
247.5 (120.8)
329.4 (177.5)
297.3 (177)

Table 3. Average CMI levels
collected at standard time
points post-transplant

Figure 1. Graphical representation in variation of average
CMI level with SD over time post-transplant.
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Average CMI levels collected at standard time points were compared between patients in the
treatment group who had at least one infection within the first-year post-transplant (N=12) and
those patients who did not experience any study-defined infections within the first year (N=19).
These results are displayed in Table 4. There were no statistically significant differences in CMI
levels at any time point post-transplant between patients with and without at least one
infectious episode within the first year.

Infection
No infection
p-value
N=12
N=19
Average CMI Day 1, ng/mL (SD)
125.6 (101.7)
317.1 (275.0)
0.07
Average CMI Week 1, ng/mL (SD)
314.5 (245.4)
426.0 (167.4)
0.2
Average CMI Week 2, ng/mL (SD)
290.8 (108.1)
358.6 (218.8)
0.4
Average CMI Week 3, ng/mL (SD)
278.0 (262.5)
356.5 (269.0)
0.5
Average CMI Week 4, ng/mL (SD)
495.2 (365.0)
420.1 (233.8)
0.5
Average CMI Month 6, ng/mL (SD)
550.7 (410.2)
347.3 (158.6)
0.14
Average CMI Month 2, ng/mL (SD)
385.6 (225.1)
408.9 (195.9)
0.8
Average CMI Month 3, ng/mL (SD)
373.1 (218.8)
336.0 (179.4)
0.6
Average CMI Month 6, ng/mL (SD)
214.9 (58.3)
271.5 (144.1)
0.3
Average CMI Month 9, ng/mL (SD)
347.6 (132.9)
321.6 (213.3)
0.8
Average CMI Year 1, ng/mL (SD)
348.0 (109.2)
268.6 (207.1)
0.3
Table 4. Comparison of average CMI levels within the treatment group in those with and
without an infectious episode.
Survival
There was no difference in 1-year survival between the two groups with 93.5% survival in the
intervention group and 93.5% survival in the control group. Two deaths occurred within the first
year in the intervention group, one from primary graft dysfunction and the second from
infectious cause, specifically pseudomonas peritonitis. Two deaths also occurred within the first
year in the control group, both deaths were from primary graft dysfunction.
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Infectious Episodes
There was no difference in the number of bacterial infections between the two groups. In the
intervention group, a total of 9 patients (29%) had a bacterial infection within the first year
compared to 12 patients (38.7%) in the control group (p=0.3). The intervention group sustained
14 bacterial infections within the first year compared to 16 bacterial infections in the control
group (p=0.6). Bacterial infections in the intervention group included: 3 episodes of clostridium
difficile colitis, 2 urinary tract infections, 2 episodes of mediastinitis, 1 empyema, 1 episode of
peritonitis, 1 episode of upper extremity cellulitis, and 4 episodes access-site infections (utilized
for temporary mechanical circulatory support post-transplant). For full comparisons of
infectious rates between groups see Table 5.
Viral infections were likewise similar between the groups. In the intervention group, a total of 9
patients (29%) had a viral infection within the first year compared to 8 patients (25.8%) in the
controls (p=0.7). There were a similar number of total viral infections, 11, in both the
intervention and control groups (p=1). Viral infections in the intervention group included: 6
episodes of CMV, 2 episodes of Norovirus, 2 episodes of respiratory syncytial virus, 1 episode of
herpes zoster, and 1 reactivation of a herpes simplex genital infection. Full comparisons are
presented in Table 5.
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Intervention
Group
N=31

Control
Group
N=31

Patients with bacterial infection, N (%)
9
12
Total number of bacterial infections, N
14
16
Patients with clostridium difficile infection, N (%)
3
5
Patients with viral infection, N (%)
9
8
Total number of viral infections, N
11
11
Patients with CMV infection, N (%)
5
8
Patients with ACR, N (%)
6
3
Patients with AMR, N (%)
3
3
Table 5. Comparison of number of infectious and rejection episodes between groups.

p-value

0.58
0.34
0.69
0.25
0.92
0.65

Transplant Rejection
Rejection episodes were similar between the two groups. In the intervention group, 6 patients
(19.4%) experienced an episode of ACR compared to 3 patients (9.7%) with ACR in the control
group (p=0.92). There were 3 episodes of AMR each within the intervention (9.7%) and control
groups (9.7%) (p=1). See Table 5 for comparisons.
Comorbidities and Immunosuppression
Renal function was similar between groups as assessed by changes over time in creatinine
(p=0.81) or GFR (p=0.69). There were no significant differences over time in markers of blood
sugar control measured via blood sugar (p=0.24) and hemoglobin A1c (p=0.82) between the two
groups. We observed no difference over time in regards to trough tacrolimus level (p=0.19) or
average dose of immunosuppressive agents between study groups – prednisone (p=0.94),
mycophenolate mofetil (p=0.09), and tacrolimus (p=0.52). Average values/levels/doses at study
enrollment and other key time points including at one-year follow up are presented in Table 6.
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Variable

Pre-Transplant
Baseline
Treatme
nt Group
(N=31)

Contr
ol
Group
(N=31
)

3 Months PostTransplant
Treatme
nt Group
(N=31)

Contr
ol
Group
(N=31)

6 Months PostTransplant
Treatme
nt Group
(N=31)

Contro
l
Group
(N=31)

1 Year PostTransplant
Treatme
nt Group
(N=31)

Contro
l
Group
(N=31)

Creatinine,
1.1
1.4
1.3
1.4
1.5
1.5
1.4
1.4
mg/dL
(0.3)
(0.5)
(0.4)
(0.3)
(0.6)
(0.6)
(0.5)
(0.3)
(SD)
Glomerular
80.2
62.7
62.9
56.9
57.8
56.7
61.2
57.8
Filtration
(30.1)
(21.5)
(22.9)
(16.8)
(24.4)
(20.6)
(22.1)
(15.5)
Rate,
mL/min/1.73
m2 (SD)
Blood Sugar,
122.8
137.5
115.6
121.1
109
112.7
117.7
112.4
mg/dL
(36.8)
(41.6)
(44.8)
(32.9)
(32.7)
(25.9)
(43.8)
(27.7)
(SD)
Hemoglobin
5.9
5.5
5.9
5.7
A1c, %
(0.7)
(0.4)
(0.9)
(0.8)
(SD)
FK level,
9.7
9.5
8
8.3
6.9
7.7
ng/mL (SD)
(2.9)
(2.6)
(2.6)
(2.7)
(3.6)
(2.4)
Tacrolimus
7.1
6
6.2
5.4
4.4
5.2
dose, mg/day
(3.2)
(3.2)
(3)
(3.8)
(3)
(3.4)
(SD)
Mycophenola
2222
2422. 1775.7
2085
1778.1
1655.
te Mofetil
(624.1)
1
(843.9) (737.7 (793.2)
2
dose, mg/day
(618)
)
(850.7
(SD)
)
Prednisone
9.6
8.1
3.8
5.3
5
4.4
dose, mg/day
(6.3)
(3.6)
(1.3)
(3)
(0)
(1.3)
(SD)
Table 6. Comparison of renal function, blood sugar control, FK level, and immunosuppressive
doses at key time points between treatment and control groups.
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CHAPTER 4: DISCUSSION
This study was the first to prospectively evaluate the utilization of a cell-mediated
immunity assay to guide tacrolimus dosing in a protocolized fashion following heart
transplantation. No difference in 1-year survival between the two groups was observed. We did
not find any difference in rates of total bacterial or viral infections, nor in specific clostridium
difficile or CMV infections. Utilizing this protocol, we did not find any difference in tacrolimus
dosing between groups, nor were there any differences between the two groups regarding
changes in renal function or markers of glucose control.
At baseline, patients in the intervention group were less likely to have been former
smokers, had better renal function, lower total bilirubin, and there was a trend toward fewer of
them being supported with LVAD at the time of transplantation compared to the control group.
This likely represents the change in the United Network of Organ Sharing (UNOS) criteria for
heart transplant allocation that occurred in October 2018, shortly after our protocol was
initiated in June 2018. Several recent studies have shown similar findings, with fewer patients
being supported with durable LVAD support and having a lesser-degree of extra-cardiac endorgan dysfunction at the time heart transplantation.15-18
Currently, monitoring for degree of immunosuppression and risk of infection, especially
within the first-year post-transplant, is performed utilizing close assessment of trough
immunosuppressant levels, appropriate immunosuppressant doses, routine laboratory markers
like WBC and lymphocyte count, as well as knowledge of both the recipient’s and donor’s
infectious history (e.g., CMV positivity). While multiple factors are utilized to assess risk
currently, these factors do not provide good insight into the actual degree of
immunosuppression achieved. Several previous studies have shown that trough levels of
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immunosuppressants4-6 and WBC and absolute lymphocyte counts6 poorly correlate with CMI as
measured by the ImmuKnow assay.
We found that cell mediated immunity levels rise slightly over the course of the first 4
weeks post-transplant with a slow decline over the remainder of the year which is a similar
trend to that observed by Rossano and colleagues in a pediatric population.6 Average levels
remained within the moderate range of cellular immune response over the course of the firstyear post-transplant. While a trend was present CMI levels immediately post-transplant
between those who would later develop an infectious episode compared to those without,
overall there were no statistically significant differences in CMI levels collected at standard time
points. While several previous studies in heart transplant patients have shown that CMI levels
are lower during or just prior to infectious episode compared to steady state or during
rejection,5,9 and early meta-analysis including various solid-organ transplants found that routine
CMI levels have a relatively low accuracy in identifying infectious risk.7
As has been reported previously,19 we found bacterial infections to be the most
common type of infection diagnosed within the first year following transplantation. While
previous retrospective reports are conflicting on whether low levels of cell-mediated immunity
are5,9 or are not predictive of infectious events,6,11 our study did not show that prospective
utilization of a cell-mediated immunity assay in a protocolized fashion to adjust tacrolimus
dosing led to a significant reduction in rates or total number of bacterial or viral infections. This
is contradictory to the only other known study to prospectively use a cell-mediated immunity
assay to guide immunosuppression following a solid organ transplant, where Ravaioli and
colleagues randomized adult patients following liver transplantation to serial immune function
testing compared to standard of practice and found that patients in the intervention group had
lower incidence of bacterial and fungal infections.12 The difference in findings is most likely
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related to variations in organ-specific management as well as the smaller sample size in our
population.
Similar to previous studies in the heart transplant population5,6,9 as well as other solidorgan transplant populations,7,12 we did not find that utilization of serial cellular immune
function testing resulted in differences in rates of ACR or AMR. Currently, there are alternative
non-invasive tests available to evaluate for the risk or presence of allograft rejection, including
gene expression profiling20 and donor-derived cell-free DNA,21 that are much more accurate and
clinically useful.
No significant differences in doses of standard immunosuppressives, including
tacrolimus, were present in our study. This is in contrast to a similar study conducted in liver
transplant recipients where Ravaioli and colleagues showed that patients who had their
tacrolimus doses adjusted based off CMI levels had lower median tacrolimus doses and trough
levels within the first 3 months and lower median doses between 6 and 12 months compared
with the standard of care group.12 We also did not observe any changes over time in markers of
renal function or diabetes control between the two groups. This most likely is a direct reflection
of the absence of similar doses of immunosuppressive agents, as doses of tacrolimus and
corticosteroids would have the biggest impact on these markers.
Limitations
While our study offers significant insight into the use of a cell-mediated immunity assay
to adjust immunosuppression in heart transplant recipients, our study is not without limitations.
First, this was a single-center study and may not be reflective of the population or clinical
practice of other centers. Second, this study was not randomized and utilized historical controls
as the comparison group, which can result in inherent biases related to changes in practice

17

habits over time. However, immunosuppression and infectious prophylaxis protocols did not
differ significantly between the two time periods. Third, adjustment of tacrolimus dosing based
on CMI results were at the discretion of the treating cardiologist and clinical pharmacist and
may have not been performed consistently between individual patients. Fourth, tacrolimus was
chosen as the immunosuppression agent of choice for adjustment based on CMI values due the
ability to follow trough levels when making appropriate adjustments along with the long-term
complications associated with tacrolimus use. It is possible that adjustments of mycophenolate
mofetil dosing based on CMI levels may be more important than adjustment of tacrolimus
dosing.
Conclusion
Utilization of a cell-mediated immunity assay at routine time points following heart
transplantation to make protocol-driven adjustments to tacrolimus doses did not result in lower
rates of infection or rejection, nor did it result in reduced doses of immunosuppressants or
improved renal function or glycemic control compared to historical controls. While assessment
of CMI may be clinically beneficial in high-risk patients with active or recent infection to help
guide management, routine use in clinically stable patients at standard time periods following
heart transplantation do not appear to be beneficial. A larger, multicenter, randomized
controlled trial may be needed to fully assess the utility of routine use of a cellular immune
function assay to adjust immunosuppression following heart transplantation, but may be
technically challenging given variations in clinical practice post-transplant across institutions.
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